Research progress of Parkinson's disease in pathophysiology

doi:10.3877/cma.j.issn.2095-123X.2023.05.010

Abstract

Abstract:

Parkinson's disease (PD) is a complex and age-related neurodegenerative disease, and its pathogenesis is still not fully understood. The occurrence and development of PD are closely related to genetic inheritance, gene mutations, mitochondrial dysfunction, oxidative stress, immune inflammatory mechanisms, gastrointestinal-related dysfunction, excessive accumulation of neuromelanin, and iron death regulation mechanisms. Various factors can cross each other and play an independent role. This paper reviews the research progress on the pathogenesis of PD in pathophysiology, aiming to seek new ideas for the treatment and drug development of PD.

Key words: Parkinson's disease, Pathophysiology, Pathogenesis

Gang Jin, Yingzhen Li, Wei Shi, Bo Li. Research progress of Parkinson's disease in pathophysiology[J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2023, 13(05): 315-319.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnkjbykfzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-123X.2023.05.010

https://zhnkjbykfzz.cma-cmc.com.cn/EN/Y2023/V13/I05/315

References 40

[1]	武雅静,张丽芳,邓远飞.帕金森病患者认知功能的临床分析[J].中华脑科疾病与康复杂志(电子版), 2019, 9(5): 271-276. DOI: 10.3877/cma.j.issn.2095-123X.2019.05.004.
[2]	张文彦,陈韦陶.帕金森病患者人格特征的研究进展[J].中风与神经疾病杂志, 2020, 37(12): 1144-1146. DOI: 10.19845/j.cnki.zfysjjbzz.2020.0543.
[3]	魏颖鸿.帕金森病基因多态性的研究进展[J].实用老年医学, 2019, 33(7): 637-641. DOI: 10.3969/j.issn.1003-9198.2019.07.004.
[4]	Trudler D, Nash Y, Frenkel D. New insights on Parkinson's disease genes: the link between mitochondria impairment and neuroinflammation[J]. J Neural Transm (Vienna), 2015, 122(10): 1409-1419. DOI: 10.1007/s00702-015-1399-z.
[5]	Singh A, Zhi L, Zhang H. LRRK2 and mitochondria: Recent advances and current views[J]. Brain Res, 2019, 1702: 96-104. DOI: 10.1016/j.brainres.2018.06.010.
[6]	刘越存.分子伴侣辅因子CHIP与帕金森病PINK1基因的相互作用研究[D].广州:南方医科大学, 2009. DOI: 10.7666/d.y1553797.
[7]	Linnertz C, Lutz MW, Ervin JF, et al. The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease[J]. Hum Mol Genet, 2014, 23(18): 4814-4821. DOI: 10.1093/hmg/ddu196.
[8]	王莉,娄桂予,卞莎莎,等.一例青少年型帕金森病患者Parkin基因的突变鉴定[J].中华医学遗传学杂志, 2019, 36(4): 344-347. DOI: 10.3760/cma.j.issn.1003-9406.2019.04.013.
[9]	Yuan X, Cao B, Wu Y, et al. Association analysis of SNP rs11868035 in SREBF1 with sporadic Parkinson's disease, sporadic amyotrophic lateral sclerosis and multiple system atrophy in a Chinese population[J]. Neurosci Lett, 2018, 664: 128-132. DOI: 10.1016/j.neulet.2017.11.015.
[10]	Giri S, Naiya T, Roy S, et al. A compound heterozygote for GCH1 mutation represents a case of atypical dopa-responsive dystonia[J]. J Mol Neurosci, 2019, 68(2): 214-220. DOI: 10.1007/s12031-019-01301-3.
[11]	Schreglmann SR, Houlden H. VPS13C-another hint at mitochondrial dysfunction in familial Parkinson's disease[J]. Mov Disord, 2016, 31(9): 1340. DOI: 10.1002/mds.26682.
[12]	许琴,罗晓光,初巧红,等.中国北方女性帕金森病患者与线粒体ND4基因A11084G位点的相关性研究[J].中华神经医学杂志, 2017, 16(4): 392-397. DOI: 10.3760/cma.j.issn.1671-8925.2017.04.013.
[13]	汪志鹏,高歌,段春礼,等. α-突触核蛋白对线粒体膜造成孔道样损伤[J].中国生物化学与分子生物学报, 2018, 34(9): 1013-1020. DOI: 10.13865/j.cnki.cjbmb.2018.09.14.
[14]	Mortiboys H, Johansen KK, Aasly JO, et al. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2[J]. Neurology, 2010, 75(22): 2017-2020. DOI: 10.1212/WNL.0b013e3181ff9685.
[15]	Hu ZL, Sun T, Lu M, et al. Kir6.1/K-ATP channel on astrocytes protects against dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease via promoting mitophagy[J]. Brain Behav Immun, 2019, 81: 509-522. DOI: 10.1016/j.bbi.2019.07.009.
[16]	Rango M, Bresolin N. Brain mitochondria, aging, and Parkinson's disease[J]. Genes (Basel). 2018, 9(5): 250. DOI: 10.3390/genes9050250.
[17]	Bury AG, Pyle A, Elson JL, et al. Mitochondrial DNA changes in pedunculopontine cholinergic neurons in Parkinson disease[J]. Ann Neurol, 2017, 82(6): 1016-1021. DOI: 10.1002/ana.25099.
[18]	Azkona G, López de Maturana R, et al. LRRK2 Expression is deregulated in fibroblasts and neurons from Parkinson patients with mutations in PINK1LRRK2 expression is deregulated in fibroblasts and neurons from Parkinson patients with mutations in PINK1[J]. Mol Neurobiol, 2018, 55(1): 506-516. DOI: 10.1007/s12035-016-0303-7.
[19]	Puspita L, Chung SY, Shim JW. Oxidative stress and cellular pathologies in Parkinson's disease[J]. Mol Brain, 2017, 10(1): 53. DOI: 10.1186/s13041-017-0340-9.
[20]	von Leden RE, Yauger YJ, Khayrullina G, et al. Central nervous system injury and nicotinamide adenine dinucleotide phosphate oxidase: oxidative stress and therapeutic targets[J]. J Neurotrauma, 2017, 34(4): 755-764. DOI: 10.1089/neu.2016.4486.
[21]	Steiner RE, Ibba M. Bridging the gap between tRNA modifications and the respiratory chain[J]. Biochemistry, 2018, 57(18): 2565-2566. DOI: 10.1021/acs.biochem.8b00377.
[22]	Krashia P, Martini A, Nobili A, et al. On the properties of identified dopaminergic neurons in the mouse substantia nigra and ventral tegmental area[J]. Eur J Neurosci, 2017, 45(1): 92-105. DOI: 10.1111/ejn.13364.
[23]	Milovanovi B, Ili J, Stankovi IM, et al. A simulation of free radicals induced oxidation of dopamine in aqueous solution[J]. Chemical Physics, 2019, 524: 26-30. DOI: 10.1016/j.chemphys.2019.05.001.
[24]	Kim A, Kozina E, Kolacheva A, et al. Cooperative synthesis of dopamine by striatal non-dopaminergic neurons as a mechanism of neuroplasticity at parkinsonism[J]. Parkinsonism & Related Disorders, 2018, 46(2): e26-e27. DOI: 10.1016/j.parkreldis.2017.11.086.
[25]	Weng M, Xie X, Liu C, et al. The sources of reactive oxygen species and its possible role in the pathogenesis of Parkinson's disease[J]. Parkinsons Dis, 2018, 2018: 9163040. DOI: 10.1155/2018/9163040.
[26]	Seaton TA, Cooper JM, Schapira AH. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors[J]. Brain Res, 1997, 777(1-2): 110-8. DOI: 10.1016/s0006-8993(97)01034-2.
[27]	Faucheux BA, Martin ME, Beaumont C, et al. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease[J]. J Neurochem, 2019, 86(5): 1142-1148. DOI: 10.1046/j.1471-4159.2003.01923.x.
[28]	Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease[J]. J Neurochem, 2010, 52(2): 381-389. DOI: 10.1111/j.1471-4159.1989.tb09133.x.
[29]	Jenner P, Dexter DT, Sian J, et al. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal kings and queens Parkinson's disease research group[J]. Ann Neurol, 1992, 32: S82-S87. DOI: 10.1002/ana.410320714.
[30]	Mogi M, Harada M, Kondo T, et al. Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease[J]. Neurosci Lett, 1995, 193(2): 129-132. DOI: 10.1016/0304-3940(95)11686-q.
[31]	De Astis S, Corradini I, Morini R, et al. Nanostructured TiO2 surfaces promote polarized activation of microglia, but not astrocytes, toward a proinflammatory profile[J]. Nanoscale, 2013, 5(22): 10963-10974. DOI: 10.1039/c3nr03534d.
[32]	Stypuła G, Kunert-Radek J, Stepień H, et al. Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with Parkinson's disease[J]. Neuroimmunomodulation, 1996, 3(2-3): 131-134. DOI: 10.1159/000097237.
[33]	Sommer A, Marxreiter F, Krach F, et al. Th17 lymphocytes induce neuronal cell death in a human iPSC-based model of Parkinson's disease[J]. Cell Stem Cell, 2018, 23(1): 123-131.e6. DOI: 10.1016/j.stem.2018.06.015.
[34]	Uemura N, Yagi H, Uemura MT, et al. Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve[J]. Mol Neurodegener, 2018, 13(1): 21. DOI: 10.1186/s13024-018-0257-5.
[35]	Pape HC, Dwenger A, Remmers D, et al. 45 Pattern of intestinal permeability changes and inflammatory response in polytrauma patients[J]. Shock, 1995, 3(5): 14.
[36]	Plascencia Germán, Perry G. Implication of ferroptosis iron-dependent programmed cell death mechanism in neurodegeneration: molecular and cell biology/oxidative stress[J]. Alzheimer's & Dementia, 2020, 16(s3): 1-2. DOI: 10.1002/alz.043978.
[37]	Umemura M, Kim JH, Aoyama H, et al. The iron chelating agent, deferoxamine detoxifies Fe(Salen)-induced cytotoxicity[J]. J Pharmacol Sci, 2017, 134(4): 203-210. DOI: 10.1016/j.jphs.2017.07.002.
[38]	姜宏,陈文芳,谢俊霞.帕金森病模型大鼠脑内多巴胺与铁含量的关系[J].生理学报, 2001, 53(5): 329-333. DOI: 10.3321/j.issn:0371-0874.2001.05.002.
[39]	Faucheux BA, Martin ME, Beaumont C, et al. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease[J]. J Neurochem, 2010, 86(5): 1142-1148. DOI: 10.1046/j.1471-4159.2003.01923.x.
[40]	Vosahlikova M, Ujcikova H, Hlouskova M, et al. Induction of oxidative stress by long-term treatment of live HEK293 cells with therapeutic concentration of lithium is associated with down-regulation of δ-opioid receptor amount and function[J]. Biochem Pharmacol, 2018, 154: 452-463. DOI: 10.1016/j.bcp.2018.06.004.

Please choose a citation manager

Content to export